Teniloxazine (also known as sulfoxazine or sufoxazine or Y 8894) was developed as an antidepressant. Teniloxazine belongs to the selective norepinephrine reuptake inhibitors (NRIs) and was studied for the treatment of the major depressive disorder. Clinical trials have shown that 50 mg of the drug lacked the anticholinergic, sedative and cardiovascular effects. In the elderly, some effects were recognized, in part, due to pharmacokinetic alteration. In addition, teniloxazine was studied for patients with Alzheimer's disease, however, doesn’t exist any development report for this study.